Case report: Disseminated cutaneous leishmaniasis resembling post-kala-azar dermal leishmaniasis caused by Leishmania donovani in three patients co-infected with visceral leishmaniasis and human immunodeficiency virus/acquired immunodeficiency syndrome in Ethiopia

American Journal of Tropical Medicine and Hygiene

Volumn 84, Issue 6, 2011, Pages 906-912

  Gelanew, Tesfaye ^a,b   Hurissa, Zewdu ^c   Diro, Ermias ^c,d   Kassahun, Aysheshm ^b   Kuhls, Katrin ^a   Schönian, Gabriele ^a   Hailu, Asrat ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ADDIS ABABA UNIVERSITY   (Ethiopia)

^c UNIVERSITY OF GONDAR   (Ethiopia)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPHOTERICIN B LIPID COMPLEX; ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MEGLUMINE ANTIMONATE; STAVUDINE; STIBOGLUCONATE SODIUM; TENOFOVIR; TUBERCULOSTATIC AGENT; MICROSATELLITE DNA; PROTOZOAL DNA; RIBOSOMAL SPACER DNA;

ABSENCE OF SIDE EFFECTS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; ETHIOPIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LEISHMANIA DONOVANI; MALE; MICROSATELLITE MARKER; MIXED INFECTION; SKIN BIOPSY; SKIN LEISHMANIASIS; SPLEEN; SPLEEN BIOPSY; VISCERAL LEISHMANIASIS; VOMITING; ADOLESCENT; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOSUPPRESSIVE TREATMENT; ISOLATION AND PURIFICATION; PARASITOLOGY; PATHOGENICITY; POLYMERASE CHAIN REACTION;

HUMAN IMMUNODEFICIENCY VIRUS; LEISHMANIA DONOVANI; NASO HEXACANTHUS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DNA, PROTOZOAN; DNA, RIBOSOMAL SPACER; ETHIOPIA; HIV; HUMANS; IMMUNOSUPPRESSION; LEISHMANIA DONOVANI; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MALE; MICROSATELLITE REPEATS; POLYMERASE CHAIN REACTION;

EID: 79958721257     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2011.11-0055     Document Type: Article

References (49)

1. Lyons S, Veeken H, Long J, 2003. Visceral leishmaniasis and HIV in Tigray, Ethiopia. Trop Med Int Health 8: 733-739. (Pubitemid 36960460)
2. Haile T, Anderson SD, 2006. Visceral leishmaniasis in northern Ethiopia. East Afr Med J 83: 389-392. (Pubitemid 44671695)
3. Mengistu G, Ayele B, 2007. Visceral leishmaniasis and HIV co-infection in patients admitted to Gondar university hospital, northwest Ethiopia. Ethiopian J Health Develop 21: 53-60.
4. Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, Dedet JP, Gradoni L, Ter Horst R, Lopez-Velez R, Moreno J, 2008. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21: 334-359. (Pubitemid 351555511)
5. Gonzalez-Beato MJ, Moyano B, Sanchez C, Gonzalez-Beato MT, Perez-Molina JA, Miralles P, Lazaro P, 2000. Kaposi's sarcoma-like lesions and other nodules as cutaneous involvement in AIDS-related visceral leishmaniasis. Br J Dermatol 143: 1316-1318. (Pubitemid 32052776)
6. Bosch RJ, Rodrigo AB, Sanchez P, de Galvez MV, Herrera E, 2002. Presence of Leishmania organisms in specific and non-specific skin lesions in HIV-infected individuals with visceral leishmaniasis. Int J Dermatol 41: 670-675. (Pubitemid 35252043)
7. Ara M, Maillo C, Peon G, Clavel A, Cuesta J, Grasa MP, Carapeto FJ, 1998. Visceral leishmaniasis with cutaneous lesions in a patient infected with human immunodeficiency virus. Br J Dermatol 139: 114-117. (Pubitemid 28338076)
8. Postigo C, Llamas R, Zarco C, Rubio R, Pulido F, Costa JR, Iglesias L, 1997. Cutaneous lesions in patients with visceral leishmaniasis and HIV infection. J Infect 35: 265-268. (Pubitemid 28025150)
9. Hurissa Z, Gebre-Silassie S, Hailu W, Tefera T, Lalloo DG, Cuevas LE, Hailu A, 2010. Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia. Trop Med Int Health 15: 848-855.
10. ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN, 2008. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 46: 1702-1709.
11. Chaudhary RG, Bilimoria FE, Katare SK, 2008. Diffuse cutaneous leishmaniasis: co-infection with human immunodeficiency virus (HIV). Indian J Dermatol Venereol Leprol 74: 641-643.
12. Gelanew T, Amogne W, Abebe T, Kuhls K, Hailu A, Schonian G, 2010. A clinical isolate of Leishmania donovani with ITS1 sequence polymorphism as a cause of para-kala-azar dermal leishmaniasis in an Ethiopian human immunodeficiency virus-positive patient on highly active antiretroviral therapy. Br J Dermatol 163: 870-874.
13. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM, 2003. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 3: 87-98. (Pubitemid 36164205)
14. Chulay JD, Bryceson AD, 1983. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 32: 475-479. (Pubitemid 13101435)
15. Schonian G, Schweynoch C, Zlateva K, Oskam L, Kroon N, Graser Y, Presber W, 1996. Identification and determination of the relationships of species and strains within the genus Leishmania using single primers in the polymerase chain reaction. Mol Biochem Parasitol 77: 19-29. (Pubitemid 26184754)
16. Schonian G, Nasereddin A, Dinse N, Schweynoch C, Schallig HD, Presber W, Jaffe CL, 2003. PCR diagnosis and characterization of Leishmania in local and imported clinical samples. Diagn Microbiol Infect Dis 47: 349-358. (Pubitemid 37101168)
17. Kuhls K, Keilonat L, Ochsenreither S, Schaar M, Schweynoch C, Presber W, Schonian G, 2007. Multilocus microsatellite typing (MLMT) reveals genetically isolated populations between and within the main endemic regions of visceral leishmaniasis. Microbes Infect 9: 334-343. (Pubitemid 46341936)
18. Gelanew T, Kuhls K, Hurissa Z, Weldegebreal T, Hailu W, Kassahun A, Abebe T, Hailu A, Schonian G, 2010. Inference of population structure of Leishmania donovani strains isolated from different Ethiopian visceral leishmaniasis endemic areas. PLoS Negl Trop Dis 4: e889.
19. Dieringer D, Schlötterer C, 2003. Microsatellite analyser (MSA): a platform independent analysis tool for large microsatellite sets. Mol Ecol Notes 3: 167-169. (Pubitemid 36374637)
20. Kumar S, Tamura K, Nei M, 2004. MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform 5: 150-163.
21. Couppie P, Clyti E, Sobesky M, Bissuel F, Del Giudice P, Sainte-Marie D, Dedet JP, Carme B, Pradinaud R, 2004. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana. Br J Dermatol 151: 1165-1171. (Pubitemid 40030163)
22. Turetz ML, Machado PR, Ko AI, Alves F, Bittencourt A, Almeida RP, Mobashery N, Johnson WD Jr, Carvalho EM, 2002. Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J Infect Dis 186: 1829-1834. (Pubitemid 35463517)
23. Barro-Traore F, Preney L, Traore A, Darie H, Tapsoba P, Bassole A, Sawadogo S, Niamba P, Grosshans E, Geniaux M, 2008. Cutaneous leishmaniasis due to Leishmania major involving the bone marrow in an AIDS patient in Burkina Faso [in French]. Ann Dermatol Venereol 135: 380-383.
24. Jafari S, Hajiabdolbaghi M, Mohebali M, Hajjaran H, Hashemian H, 2010. Disseminated leishmaniasis caused by Leishmania tropica in HIV-positive patients in the Islamic Republic of Iran. Mediterranean Health Journal 16: 3041-3044.
25. Alvar J, Gutierrez-Solar B, Pachon I, Calbacho E, Ramirez M, Valles R, Guillen JL, Canavate C, Amela C, 1996. AIDS and Leishmania infantum. New approaches for a new epidemiological problem. Clin Dermatol 14: 541-546.
26. Colebunders R, Depraetere K, Verstraeten T, Lambert J, Hauben E, Van Marck E, Maurer T, Banuls AL, Dujardin JC, 1999. Unusual cutaneous lesions in two patients with visceral leishmaniasis and HIV infection. J Am Acad Dermatol 41: 847-850. (Pubitemid 29514005)
27. Antinori S, Longhi E, Bestetti G, Piolini R, Acquaviva V, Foschi A, Trovati S, Parravicini C, Corbellino M, Meroni L, 2007. Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. Br J Dermatol 157: 1032-1036. (Pubitemid 47583507)
28. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC Jr, Hamill RJ, 2005. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 19: 399-406. (Pubitemid 40446186)
29. Boumis E, Chinello P, Della Rocca C, Paglia MG, Proietti MF, Petrosillo N, 2006. Atypical disseminated leishmaniasis resembling post-kala-azar dermal leishmaniasis in an HIV-infected patient. Int J STD AIDS 17: 351-353. (Pubitemid 43668178)
30. al Jaser M, el-Yazigi A, Kojan M, Croft SL, 1995. Skin uptake, distribution, and elimination of antimony following administration of sodium stibogluconate to patients with cutaneous leishmaniasis. Antimicrob Agents Chemother 39: 516-519.
31. Agostoni C, Dorigoni N, Malfitano A, Caggese L, Marchetti G, Corona S, Gatti S, Scaglia M, 1998. Mediterranean leishmaniasis in HIV-infected patients: epidemiological, clinical, and diagnostic features of 22 cases. Infection 26: 93-99. (Pubitemid 28142927)
32. Pratlong F, Rioux JA, Marty P, Faraut-Gambarelli F, Dereure J, Lanotte G, Dedet JP, 2004. Isoenzymatic analysis of 712 strains of Leishmania infantum in the south of France and relationship of enzymatic polymorphism to clinical and epidemiological features. J Clin Microbiol 42: 4077-4082. (Pubitemid 39296127)
33. Kallel K, Pratlong F, Haouas N, Kaouech E, Belhadj S, Anane S, Dedet JP, Babba H, Chaker E, 2008. Isoenzymatic variability of Leishmania infantum in Tunisia concerning 254 human strains. Acta Trop 106: 132-136.
34. Mahdi M, Elamin EM, Melville SE, Musa AM, Blackwell JM, Mukhtar MM, Elhassan AM, Ibrahim ME, 2005. Sudanese mucosal leishmaniasis: isolation of a parasite within the Leishmania donovani complex that differs genotypically from L. donovani causing classical visceral leishmaniasis. Infect Genet Evol 5: 29-33. (Pubitemid 39619015)
35. Lewin S, Schonian G, El Tai N, Oskam L, Bastien P, Presber W, 2002. Strain typing in Leishmania donovani by using sequence-confirmed amplified region analysis. Int J Parasitol 32: 1267-1276. (Pubitemid 35232178)
36. El Tai NO, El Fari M, Mauricio I, Miles MA, Oskam L, El Safi SH, Presber WH, Schonian G, 2001. Leishmania donovani: intraspecific polymorphisms of Sudanese isolates revealed by PCR-based analyses and DNA sequencing. Exp Parasitol 97: 35-44. (Pubitemid 32989014)
37. Alam MZ, Kuhls K, Schweynoch C, Sundar S, Rijal S, Shamsuzzaman AK, Raju BV, Salotra P, Dujardin JC, Schonian G, 2009. Multilocus microsatellite typing (MLMT) reveals genetic homogeneity of Leishmania donovani strains in the Indian subcontinent. Infect Genet Evol 9: 24-31.
38. Mohamed HS, Ibrahim ME, Miller EN, Peacock CS, Khalil EA, Cordell HJ, Howson JM, El Hassan AM, Bereir RE, Blackwell JM, 2003. Genetic susceptibility to visceral leishmaniasis in the Sudan: linkage and association with IL4 and IFNGR1. Genes Immun 4: 351-355. (Pubitemid 38961142)
39. Blackwell JM, Mohamed HS, Ibrahim ME, 2004. Genetics and visceral leishmaniasis in the Sudan: seeking a link. Trends Parasitol 20: 268-274.
40. Stark D, Pett S, Marriott D, Harkness J, 2006. Post-kala-azar dermal leishmaniasis due to Leishmania infantum in a human immunodeficiency virus type 1-infected patient. J Clin Microbiol 44: 1178-1180.
41. Bittencourt A, Silva N, Straatmann A, Nunes VL, Follador I, Badaro R, 2002. Post-kala-azar dermal leishmaniasis associated with AIDS. Braz J Infect Dis 6: 313-316.
42. Rihl M, Stoll M, Ulbricht K, Bange FC, Schmidt RE, 2006. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from western Europe. J Infect 53: e25-e27. (Pubitemid 43960448)
43. Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, Seaman J, Davidson RN, 2001. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 95: 668-672. (Pubitemid 34202261)
44. Sepkowitz KA, 2001. AIDS-the first 20 years. N Engl J Med 344: 1764-1772.
45. el Hassan AM, Ghalib HW, Zijlstra EE, Eltoum IA, Satti M, Ali MS, Ali HM, 1992. Post kala-azar dermal leishmaniasis in the Sudan: clinical features, pathology and treatment. Trans R Soc Trop Med Hyg 86: 245-248.
46. Ismail A, El Hassan AM, Kemp K, Gasim S, Kadaru AE, Moller T, Kharazmi A, Theander TG, 1999. Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile. J Pathol 189: 615-622.
47. Ridolfo AL, Gervasoni C, Antinori S, Pizzuto M, Santambrogio S, Trabattoni D, Clerici M, Galli M, 2000. Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected with Leishmania infantum. J Infect 40: 199-202. (Pubitemid 30312566)
48. Gasim S, Elhassan AM, Kharazmi A, Khalil EA, Ismail A, Theander TG, 2000. The development of post-kala-azar dermal leishmaniasis (PKDL) is associated with acquisition of Leishmania reactivity by peripheral blood mononuclear cells (PBMC). Clin Exp Immunol 119: 523-529.
49. Lawn SD, Wilkinson RJ, 2006. Immune reconstitution disease associated with parasitic infections following antiretroviral treatment. Parasite Immunol 28: 625-633. (Pubitemid 44581388)